SGYP

Synergy Pharmaceuticals Inc Has New IBS-C Indication Under Its Belt, But Can Trulance Succeed Long-Term?

Canaccord’s John Newman finds SGYP’s Trulance commercial potential enticing down the line against its competitors.

Julie Lamb — January 25, 2018, 4:25 PM EDT

Synergy Pharmaceuticals Inc Enters a Fiercely Competitive IBS-C Market, But “Attractive Commercial Opportunities” Exist, Says William Tanner

Now that SGYP has won over FDA approval in a new indication (IBS-C), did the biotech company’s competitive edge just get sharper?

Julie Lamb — January 25, 2018, 9:09 AM EDT

Can Synergy Pharmaceuticals Inc Get Things Moving Again with Trulance?

Wednesday could mark a turning point for Synergy investors.

Smarter Team — January 23, 2018, 9:42 AM EDT

Synergy Pharmaceuticals: Analyst Questions Whether Label Expansion for Trulance Will Prove to Be a “Meaningful” Driver

Ahead of the fourth quarter showcase from Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) anticipated March 7th, first comes a PDUFA date of FDA judgment for …

Julie Lamb — January 22, 2018, 12:20 PM EDT

Synergy Pharmaceuticals Inc (SGYP) Savvy Leadership Turnover and Upcoming Trulance Approval in IBS-C Have This Bull Confident

H.C.

Julie Lamb — January 9, 2018, 9:03 AM EDT

Dilution Fears Continue to Hit Synergy Pharmaceuticals Inc (SGYP); Oppenheimer Downgrades the Stock

Nagging capital overhang moves us to sidelines, says Derek Archila.

Jason Cohen — January 5, 2018, 11:43 AM EDT

Tim Chiang Upbeat on These Two Biotech Players Circling FDA Approvals in 2018: Synergy Pharmaceuticals Inc., Progenics Pharmaceuticals

As SGYP and PGNX both await potential FDA approvals this year, BTIG’s Tim Chiang shares his positive two cents on these drug makers he believes present meaningful upside potential.

Julie Lamb — January 4, 2018, 2:20 PM EDT